Last Updated : May 10, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Verquvo | vericiguat | Heart failure | Reimburse with clinical criteria and/or conditions | Complete | ||
| Verkazia | cyclosporine | Severe vernal keratoconjunctivitis, pediatric (≥4 years) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta in combo Rituximab | Venetoclax | Chronic Lymphocytic Leukemia (CLL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | Venetoclax Obinutuzumab | Obinutuzumab for CLL | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | Venetoclax | Chronic Lymphocytic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | venetoclax | Acute myeloid leukemia | Do not reimburse | Complete | ||
| Venclexta | venetoclax | Acute myeloid leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Venclexta | venetoclax | Chronic lymphocytic leukemia (CLL). | Pending | |||
| Venclexta | Venetoclax | Withdrawn | ||||
| Vemlidy | tenofovir alafenamide | Hepatitis B, chronic | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 10, 2024